FDA: Doctors should use genetic test before prescribing abacavir
The FDA is expected to release an advisory today that calls on doctors to use a genetic test before prescribing abacavir -- sold by GlaxoSmithKline under the name Ziagen -- to prevent severe allergic reactions in patients carrying an immune-system gene variant. The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on "inconclusive" study data.
New York Times, The | 07/24
This story published in AHIP Solutions SmartBrief on 07/24/2008
More from SmartBrief:
FDA looks into cancer concerns related to insulin Lantus
Thursday, July 2, 2009
FDA clears 6 more doses of Hospira's heparin
Tuesday, September 1, 2009
FDA launches Web-based guide about hearing aids
Tuesday, November 3, 2009
Get stories like these delivered daily for FREE:
|
AHIP Solutions SmartBrief
Designed specifically for health care executives like you, AHIP Solutions SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|